Cargando…

Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy

BACKGROUND: Lung cancer is the leading cause of cancer deaths worldwide (1.38 million cancer deaths, 18.2% of the total) and of cancer morbidity (1.61 million new cases, 12.7% of all new cancers). Currently only three second-line non-small-cell lung cancer (NSCLC) pharmacotherapies are licensed in t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwander, Bjoern, Ravera, Simona, Giuliani, Giovanni, Nuijten, Mark, Walzer, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3435091/ https://www.ncbi.nlm.nih.gov/pubmed/22969300 http://dx.doi.org/10.2147/CEOR.S34371

Ejemplares similares

Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
por: Mickisch, G H J, et al.
Publicado: (2010)

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
por: Mickisch, G, et al.
Publicado: (2010)

The cost of unresectable stage III or stage IV melanoma in Italy
por: Maio, Michele, et al.
Publicado: (2012)

The cost of the migraine patient in Italy
por: Roncolato, Maurizio, et al.
Publicado: (2000)

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
por: Vergnenègre, Alain, et al.
Publicado: (2012)

Cost of lampf linac options
por: Schaffer, G
Publicado: (1989)

Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
por: Franchi, Matteo, et al.
Publicado: (2022)

Cost of persistent asthma in Italy
por: Dal Negro, Roberto W., et al.
Publicado: (2016)

Second-line treatment options in hepatocellular carcinoma
por: Marino, Donatella, et al.
Publicado: (2019)

Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
por: Chiang, Chi-leung, et al.
Publicado: (2021)

Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia
por: Goshua, George, et al.
Publicado: (2022)

Cost effectiveness of palivizumab in Spain: an analysis using observational data
por: Nuijten, Mark J., et al.
Publicado: (2009)

Pursuing Elimination of Hepatitis C in Egypt: Cost-Effectiveness and Economic Evaluation of a Country-Wide Program
por: Schwander, Bjoern, et al.
Publicado: (2022)

An On-Line Low-Cost Irradiance Monitoring Network with Sub-Second Sampling Adapted to Small-Scale PV Systems
por: Espinosa-Gavira, Manuel Jesús, et al.
Publicado: (2018)

Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China
por: Shi, Yafei, et al.
Publicado: (2021)

Provisional Report on the Total Cost for the Second Stage of the PS Improvements Programme
Publicado: (1972)

Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India
por: Gupta, Dharna, et al.
Publicado: (2023)

Cost-Utility Analysis: Current Methodological Issues and Future Perspectives
por: Nuijten, Mark J. C., et al.
Publicado: (2011)

Implication of First-Line Antiretroviral Therapy Choice on Second-Line Options
por: Meloni, Seema T, et al.
Publicado: (2017)

An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer
por: Patel, Shetal, et al.
Publicado: (2021)

A cost-of-illness study of spina bifida in Italy
por: Colombo, Giorgio L, et al.
Publicado: (2013)

Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China
por: Xiang, Guiyuan, et al.
Publicado: (2023)

Healthcare costs of diabetic foot disease in Italy: estimates for event and state costs
por: Seghieri, Chiara, et al.
Publicado: (2022)

Actuarial Cost Analysis for options on the Future of the Fund
Publicado: (2016)

Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy
por: Bonifacio, Massimiliano, et al.
Publicado: (2021)

Cost-effectiveness of prucalopride in the treatment of chronic constipation in the Netherlands
por: Nuijten, Mark J. C., et al.
Publicado: (2015)

First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis
por: Neyt, Mattias, et al.
Publicado: (2018)

A Budget-Impact and Cost-Effectiveness Model for Second-Line Treatment of Major Depression
por: Malone, Daniel C.
Publicado: (2007)

Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer
por: Giuliani, Jacopo, et al.
Publicado: (2021)

Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

Cost of illness of urothelial bladder cancer in Italy
por: Gerace, Claudio, et al.
Publicado: (2017)

The social cost of chronic kidney disease in Italy
por: Turchetti, Giuseppe, et al.
Publicado: (2016)

Health economics evidence for medical nutrition: are these interventions value for money in integrated care?
por: Walzer, Stefan, et al.
Publicado: (2014)

Health economic analyses in medical nutrition: a systematic literature review
por: Walzer, Stefan, et al.
Publicado: (2014)

Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium
por: Annemans, Lieven, et al.
Publicado: (2014)

Hospital costs of central line-associated bloodstream infections and cost-effectiveness of closed vs. open infusion containers. The case of Intensive Care Units in Italy
por: Tarricone, Rosanna, et al.
Publicado: (2010)

Treatment options for second-stage gambiense human African trypanosomiasis
por: Eperon, Gilles, et al.
Publicado: (2014)

Cost Recommendations in the Second Edition of Cost-Effectiveness in Health and Medicine: A Review
por: Nyman, John A.
Publicado: (2018)

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
por: Zhou, Dongchu, et al.
Publicado: (2022)

Late presentation increases risk and costs of non-infectious comorbidities in people with HIV: an Italian cost impact study
por: Guaraldi, Giovanni, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_32npcq04ei870c8ous3q9uuo7s